May 18, 2021 / 08:50PM GMT
Daniel James Busby - RBC Capital Markets, Research Division - Assistant VP
All right. Thank you for joining us, everyone. I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets, and I'm pleased to be joined by AbbVie for our next presentation.
Joining us this afternoon are Mike Severino, Vice Chairman and President; Rob Michael, Executive Vice President and CFO; Jeff Stewart, Executive Vice President of Commercial Operations; and Liz Shea, Head of IR. So thank you all for being here.
There's a lot to talk about. And given the limited time we have, I think it makes sense to jump right into Q&A.
Questions and Answers:
Daniel James Busby - RBC Capital Markets, Research Division - Assistant VPSo maybe to begin with the immunology business. I'd like to talk a little bit about Humira, SKYRIZI and RINVOQ, obviously, a lot going on. Humira and SKYRIZI already blockbuster products, RINVOQ is well on its way. Late last year, you provided combined 0.25 risk-adjusted sales guidance for SKYRIZI and RINVOQ of greater than $15 billion.
Trustpilot
